Abstract
Kraepelin (1) and Bleuler (2) in their seminal writings pointed out that “genuine depression” frequently occurred in schizophrenic patients and suggested that dysphoric mood arose due to awareness of the disorder and its limiting influence on their life. In the formal development of mental disorder taxonomies a preference was expressed for orthogonal dimensions which implied that pure schizophrenia excluded depression. The sheer weight of clinical observations that depressive features occurred in schizophrenic patients was tentatively acknowledged in the designation of “Schizoaffective Disorder” and DSM-III-R (3) (p. 208) notes that this “represents one of the most confusing and controversial concepts in psychiatric nosology”. Some investigators interpreted “depression-like” symptoms to be manifestations of Bleuler’s symptoms, now rediscovered and referred to as “negative symptoms”. These include affective flattening and alogia. Still others have suggested that depressed states are pharmacogenically induced (4–6). This latter idea has not received support in more recent and properly controlled investigations (7, 8).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kraepelin E: Dementia Praecox and Paraphrenia. Edinburgh, Livingstone, 1919.
Bleuler E: Dementia Praecox or the Group of Schizophrenias. New York, International Universities Press, 1950.
American Psychiatric Association: Diagnostic and Statistical Manual, Third Edition, Revised. Washington, D.C., APA, 1987.
De Alarcon R, Carney MWP: Severe depressive mood change following slow-release intramuscular fluphenazine injection. Br Med J 3: 564–567, 1969.
Floru L, Heinrich K, Wittek F: The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Int Pharmacopsychiatry 10: 230–239, 1975.
Keskiner A: A long-term follow-up of fluphenazine enanthate treatment. Curr Ther Res 15: 305–313, 1973.
Hogarty GE, Munetz MR: Pharmacogenic depression among outpatient schizophrenic patients: A failure to substantiate. J Clin Psychopharmacol 4: 17–24, 1984.
Wistedt B, Palmstierna T: Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. J Clin Psychiatry 44: 369–371, 1983.
Crow TJ: The continuum of psychosis and its implication for the structure of the gene. Br J Psychiatry 149: 419–429, 1986.
Martin RL, Cloninger CR, Guze SB, Clayton PJ: Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 46: 9–13, 1985.
Glazew W, Prusoff B, John K, et al: Depression and social adjustment among chronic schizophrenia outpatients. J Nery Ment Dis 169: 712–717, 1981.
Herz MI, Melville C: Relapse in schizophrenia. Am J Psychiatry 137: 801–805, 1980.
Drake RE, Gates C, Cotton PG: Suicide among schizophrenics: a comparison of attempters and completed suicides. Br J Psychiatry 149: 784–787, 1986.
Black DW, Winokur G, Warrack G: Suicide in schizophrenia: The Iowa Record Linkage Study. J Clin Psychiatry 46: 14–17, 1985.
Loranger AW: Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry 46: 157–161, 1984.
Beck AT, Weissman A, Lester D, Trexler L: The measure of pessimism: The Hopelessness Scale. J Consult Clin Psychol 42: 861–865, 1974.
Andreasen NC: Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry 39: 784–788, 1982.
Seitz R: Five psychological measures of neurotic depression: A correlation study. J Clin Psychol 26: 504–505, 1970.
Turner JA, Romano JM: Self-report screening measures for depression in chronic pain patients. J Clin Psychol 40: 909–913, 1984.
Holland TR, Levi M, Watson CG: MMPI basic scales vs. two-point codes in the discrimination of psychopathological groups. J Clin Psychol 37: 394–396, 1981.
Rosen A: Differentiation of diagnostic groups by individual MMPI scales. J Consult Psychol 22: 453–457, 1958.
Dalby JT, Williams R: Depression in schizophrenia: The influence of intelligence. Can J Psychiatry 32: 816–817, 1987.
Walters GD: The MMPI and schizophrenia: A review. Schizoph Bull 9: 226–246, 1983.
Kleinke CL: Comparing depression-coping strategies of schizophrenic men and depressed and non-depressed college students. J Clin Psychol 40: 420–426, 1984.
Johnson DAW: Studies of depressive symptoms in schizophrenia I. The prevalence of depression and its possible causes. Br J Psychiatry 139: 89–101, 1981.
Leff J, Tress K, Edwards B: The clinical course of depressive symptoms in schizophrenia. Schizophrenia Research 1: 25–30, 1988.
Rush AJ, Khatami M, Beck AT: Cognitive and behavior therapy in chronic depression. Behavior Therapy 6: 398–404, 1975.
Siris SG, Strahan A, Mendeli J, Cooper TB, Casey E: Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression. Schizophrenia Research 1: 31–35, 1988.
Baldessarini RJ, Cohen BM, Teicher MH: Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79–91, 1988.
Schneier FR, Siris SG: A review of psychoactive substance use and abuse in schizophrenia: Patterns of drug choice. J Nery Ment Dis 175: 641–652, 1987.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer Science+Business Media New York
About this paper
Cite this paper
Williams, R., Dalby, J.T. (1989). Drug and Subject Influences on Measures of Depression and Negative Symptoms in Schizophrenic Patients. In: Williams, R., Dalby, J.T. (eds) Depression in Schizophrenics. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9978-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9978-1_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9980-4
Online ISBN: 978-1-4757-9978-1
eBook Packages: Springer Book Archive